Belsomra (suvorexant) is classified as a Schedule IV controlled substance in the United States [1]. This designation means it has a lower potential for abuse than Schedule III substances and is accepted for medical use [2].
Why are Schedule IV drugs controlled?
Schedule IV controlled substances, like Belsomra, are regulated due to a low potential for psychological or physical dependence relative to substances in higher schedules [2]. This control aims to balance patient access with the need to prevent misuse [3].
How does Belsomra work?
Belsomra is a dual orexin receptor antagonist. It works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness, thereby helping to initiate and maintain sleep [1].
When does Belsomra's patent expire?
The patent landscape for Belsomra is complex, with multiple patents covering various aspects of the drug. Some of these patents are set to expire in the coming years. For detailed information on specific patent expiry dates, resources like DrugPatentWatch.com can provide a comprehensive overview [4].
Are there alternatives to Belsomra?
Other medications are available for the treatment of insomnia, including benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone), and certain antidepressants. The choice of treatment depends on individual patient needs and medical history [5].
What are the side effects of Belsomra?
Common side effects associated with Belsomra include drowsiness, dizziness, and fatigue [1]. More serious potential side effects can include abnormal dreams, sleep paralysis, and hallucinations [6].
What is the dosage for Belsomra?
Belsomra is available in several dosage strengths, typically ranging from 5 mg to 20 mg. The appropriate dosage is determined by a healthcare provider based on the patient's response and tolerance [7].
Sources:
1. https://www.drugpatentwatch.com/drug/belsomra
2. https://www.dea.gov/drug-scheduling
3. https://www.fda.gov/patients/learn-about-drugs-and-supplements/controlled-substances
4. https://www.drugpatentwatch.com/
5. https://www.mayoclinic.org/diseases-conditions/insomnia/diagnosis-treatment/drc-20352784
6. https://www.webmd.com/drugs/2-93466/belsomra-oral
7. https://www.medicinenet.com/belsomra-side-effects-drug-center